A naukri.com initiative
Brighter Side of News
1M
351
Image Credit: Brighter Side of News
Scientists develop microcellular drones to deliver cancer-killing drugs
- Non-small cell lung cancer (NSCLC) with genetic changes like EGFR mutations poses challenges due to drug resistance.
- Third-generation TKI, osimertinib, targets EGFR mutations but faces limitations from new mutations like C797 residue.
- Antisense oligonucleotides (ASOs) offer promise by silencing genes linked to cancer progression, providing a tailored approach.
- Delivery challenges for ASOs are tackled by using red blood cell-derived EVs (RBCEVs) for precise targeting and minimal side effects.
- Combining ASOs with RBCEVs shows potent anti-cancer effects in laboratory and patient-derived cell models.
- This innovative approach published in eBioMedicine advances precision medicine by targeting specific genetic mutations in cancer cells.
- RBCEVs as delivery vehicles have advantages like large-scale production, tissue-specific targeting, and reduced immune reactions.
- Success with ASO-loaded RBCEVs in preclinical models opens doors for human trials and potential broader applications in cancer treatment.
- Adaptability of ASOs to new mutations aligns with the need to outpace cancer's genetic changes, offering hope for improved outcomes in cancers like NSCLC.
- Innovations like RBCEVs and ASOs in precision medicine signify a step towards personalized cancer treatment for better patient outcomes.
Read Full Article
21 Likes
For uninterrupted reading, download the app